Get the Stockscreener App
2.365
1.46%
-0.035
Milestone Pharmaceuticals Inc stock is traded at $2.365, with a volume of 2.64M.
It is down -1.46% in the last 24 hours and up +25.80% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$2.40
Open:
$2.49
24h Volume:
2.64M
Relative Volume:
1.59
Market Cap:
$201.43M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.7014
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
+1.94%
1M Performance:
+25.80%
6M Performance:
+53.57%
1Y Performance:
+28.53%
1-Day Range:
$2.32
$2.49
1-Week Range:
$2.26
$2.50
52-Week Range:
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
2.365 | 204.41M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.04 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.84 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.12 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
903.91 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.77 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | Wells Fargo | Overweight |
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Milestone Pharmaceuticals Inc. (MIST) stock price, news, quote and history - Yahoo Finance UK
Milestone Pharmaceuticals Inc. (MIST) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is Milestone Pharmaceuticals Inc. stock bottoming outJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
How analysts rate Milestone Pharmaceuticals Inc. stock today2025 Market Trends & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-11-20 02:01:48 - newser.com
Can Milestone Pharmaceuticals Inc. recover in the next quarter2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Published on: 2025-11-19 17:33:54 - newser.com
Why analysts remain bullish on Milestone Pharmaceuticals Inc. stockJuly 2025 PreEarnings & Intraday High Probability Setup Alerts - newser.com
Published on: 2025-11-19 13:39:11 - newser.com
Published on: 2025-11-19 06:17:41 - newser.com
Using Bollinger Bands to evaluate Milestone Pharmaceuticals Inc.Weekly Volume Report & AI Powered Market Entry Ideas - newser.com
How Milestone Pharmaceuticals Inc. stock reacts to oil pricesTreasury Yields & Daily Market Momentum Tracking - newser.com
How to forecast Milestone Pharmaceuticals Inc. trends using time series2025 Year in Review & Stock Portfolio Risk Control - newser.com
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate - Yahoo Finance
Will Milestone Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Volume Leaders & Weekly Momentum Picks - newser.com
Can Milestone Pharmaceuticals Inc. stock resist sector downturns2025 Price Momentum & Expert Approved Trade Ideas - newser.com
Is it too late to sell Milestone Pharmaceuticals Inc.Weekly Stock Report & Safe Swing Trade Setups - newser.com
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet? - simplywall.st
Combining price and volume data for Milestone Pharmaceuticals Inc.Trade Risk Report & Capital Efficiency Focused Ideas - newser.com
Will Milestone Pharmaceuticals Inc. stock benefit from commodity pricesTrade Risk Summary & Weekly Top Performers Watchlists - Fundação Cultural do Pará
Jefferies raises Milestone Pharmaceuticals stock price target to $2 from $1 - Investing.com Canada
What the charts say about Milestone Pharmaceuticals Inc. todayWeekly Gains Summary & Daily Chart Pattern Signals - newser.com
Milestone Pharmaceuticals Reports Q3 2025 Financial Results - TipRanks
Milestone Pharmaceuticals: Q3 Earnings Snapshot - Norwalk Hour
Milestone Pharma Q3 net loss widens on commercial expenses - MarketScreener
Milestone Pharmaceuticals Announces PDUFA Target Date for CARDAMYST™ Nasal Spray as December 13, 2025, with Promotional Launch Plans in Place - Quiver Quantitative
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone Pharmaceuticals Reports Third Quarter 2025 - GlobeNewswire
Milestone Pharma (Nasdaq: MIST) has Dec 13 PDUFA target for CARDAMYST in PSVT; launch plans set - Stock Titan
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
3.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):